Previous 10 | Next 10 |
Homology Medicines is a US-based genetic medicines biotech company aiming to treat rare genetic diseases with an unmet medical need. Homology Medicines has a pipeline of 1 Phase 1/2 therapeutic (HMI-102), 3-IND-enabling phase therapeutics, and 3 in the early research phase on top of t...
Gainers: BioCardia (BCDA) +102%.Arvinas (ARVN) +91%.Rubius Therapeutics (RUBY) +56%.Veru (VERU) +48%.AnPac Bio-Medical Science (ANPC) +45%.Homology Medicines (FIXX) +32%.ReneSola (SOL) +32%.Alexion Pharmaceuticals (ALXN) +31%.BioLineRx (BLRX) +30%.Big Rock Partners Acquisition (BRPA...
BioMarin is a leader in rare disease therapy discovery with multiple competitive advantages including scale, expertise, patents and relationships. Two major catalysts for 2021 provide investors with favorable risk/reward skew afforded by a low share price that should not be ignored. ...
Homology Medicines (FIXX): Q3 GAAP EPS of -$0.62 beats by $0.18.Revenue of $0.57M (+29.5% Y/Y) beats by $0.04M.Shares -0.4%.Press Release For further details see: Homology Medicines EPS beats by $0.18, beats on revenue
- Based on Positive Data , Advancing pheNIX Gene Therapy Clinical Trial for PKU to Dose Expansion Phase - - $60 Million Equity Investment from Pfizer Inc. - - Unveiled In Vivo Gene Therapy Program for Hunter Syndrome - BEDF...
Homology Medicines (FIXX) jumps 20% in premarket on xxx volume after securing equity investment of $60M from Pfizer (PFE) and purchase 5M Homology shares at $12/share.In connection with the investment, Pfizer’s Dr. Cheng will join Homology’s Scientific Advisory Board t...
BEDFORD, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Pfizer Inc. (NYSE: PFE) has agreed to make a $60 million equity investment in Homology. Pfizer has agreed to purchase 5,000,000 of Homology’s c...
Homology Medicines plunges ([[FIXX]] -21.4%) on high volume as investors appear underwhelmed with results from dose-escalation portion of the Phase 1/2 study evaluating its gene therapy (HMI-102) for phenylketonuria ((PKU)), a rare inherited disorder characterized by an inability to brea...
- Marked Reductions in Phe Observed at Two Dose s - - Achieved Goal with Plans to Advance to Randomized, Concurrently Controlled Expansion Phase of Trial...
Homology Webcast / Conference Call Scheduled for Friday, November 6 at 4:30 p.m. ET BEDFORD, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the upcoming oral presentation of data from the dose-escala...
News, Short Squeeze, Breakout and More Instantly...
Homology Medicines Inc. Company Name:
FIXX Stock Symbol:
NASDAQ Market:
Homology Medicines Inc. Website:
2024-03-25 09:02:02 ET Homology Medicines Inc (FIXX) announced stock split at a ratio of 1-for-18 on 2024-03-25 ... Full story available on KlickAnalytics.com
BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right (CVR) for each outstandi...
Homology Medicines has an initial 180-day period through June 26, 2024 to regain compliance with Minimum Bid Price Requirement BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it received notification (“ Nasdaq Notif...